Tanzania Medicines and Medical Devices Authority Bans Levamisole-Containing Products

The Tanzania Medicines and Medical Devices Authority (TMDA) has issued an immediate ban on all human medicinal products containing Levamisole as an active pharmaceutical ingredient, effective June 23, 2026. This decisive action follows comprehensive pharmacovigilance activities that identified serious safety concerns, including the risk of Leukoencephalopathy, a severe neurological disorder. The ban prohibits the manufacturing, importation, distribution, wholesale supply, retail sale, and human use of these products within Tanzania. Importers and distributors are mandated to cease supply and initiate a product recall within 14 days, with the public advised to surrender any existing Levamisole-containing medications to TMDA offices. This move underscores the TMDA's commitment to public health and aligns with similar regulatory actions taken by other international bodies.

In a significant regulatory development, the Tanzania Medicines and Medical Devices Authority (TMDA) announced an immediate and comprehensive ban on all human medicinal products containing Levamisole as an active pharmaceutical ingredient. This directive, issued on June 23, 2026, marks a critical step in safeguarding public health by removing from the market a drug now deemed to pose unacceptable risks to patients. The ban extends across the entire supply chain, from manufacturing and importation to distribution, sale, and ultimate human use, necessitating a swift and coordinated response from all stakeholders in the pharmaceutical sector.

This regulatory action stems from the TMDA's ongoing pharmacovigilance activities, which revealed compelling evidence of serious adverse effects associated with Levamisole. Specifically, the Authority highlighted the risk of Leukoencephalopathy, a severe neurological disorder, among other potential health complications. The TMDA's decision reflects a rigorous benefit-risk assessment, concluding that the identified risks far outweigh any therapeutic benefits previously attributed to Levamisole.

For legal professionals and entities operating within Tanzania's pharmaceutical landscape, this ban carries immediate and far-reaching implications. It mandates strict compliance with recall procedures and necessitates a thorough review of product portfolios and supply chain operations. This article will delve into the statutory basis for the TMDA's authority, the specific reasons underpinning the ban, and the practical steps required for compliance, while also considering the broader context of drug regulation and patient safety.

The Tanzania Medicines and Medical Devices Authority (TMDA) operates as an Executive Agency under the Ministry of Health, deriving its mandate from the Tanzania Medicines and Medical Devices Act, Cap 219 (Revised Edition 2023). This foundational legislation empowers the TMDA to regulate the quality, safety, and efficacy of medicines, medical devices, herbal drugs, and poisons within Tanzania. Key functions of the Authority include regulating manufacturing, importation, distribution, and sale of these products, prescribing quality standards, conducting inspections, and evaluating and registering medicines for market authorization.

A crucial aspect of the TMDA's regulatory framework is its robust pharmacovigilance system. The Tanzania Food, Drugs and Cosmetics (Pharmacovigilance) Regulations, 2018, establish a comprehensive framework for monitoring and ensuring the safety of pharmaceutical products post-market approval. This system involves collecting, analyzing, and evaluating safety reports from both local and international sources, which are then presented to the Vigilance Technical Committee (VTC) for risk assessment and regulatory recommendations. Section 51 of the Tanzania Medicines and Medical Devices Act, Cap 219, further grants the Authority the power to impose any requirement deemed necessary in the public interest at any time during a medicine's lifecycle.

Levamisole, the active pharmaceutical ingredient at the center of this ban, has historically been used as an anti-parasitic agent for treating worm infections, such as roundworm and hookworm. In some contexts, it has also seen limited use as an immunomodulatory agent and as an adjuvant in certain cancer therapies. However, its use in human medicine has declined significantly in various jurisdictions due to the emergence of severe adverse effects.

The TMDA's decision to ban Levamisole-containing products for human use is a direct consequence of its rigorous pharmacovigilance processes. The Authority's Vigilance Technical Committee (VTC) evaluated safety reports from both local and international sources, which consistently highlighted a significant risk profile associated with Levamisole. The primary concern identified is Leukoencephalopathy, a serious neurological disorder affecting the brain's white matter, which can lead to severe complications, including permanent neurological damage and death if not promptly diagnosed and treated.

Beyond Leukoencephalopathy, other serious adverse effects linked to Levamisole include agranulocytosis (a drastic reduction in white blood cells, increasing susceptibility to infections) and vasculitis (inflammation of blood vessels). These findings led the TMDA to conclude that the risks associated with Levamisole unequivocally outweigh its therapeutic benefits, particularly given the availability of safer alternative treatments for worm infections. This risk-benefit assessment is central to modern drug regulation, where a medicine's continued market authorization is contingent upon its demonstrated safety and efficacy relative to its intended use.

The scope of the ban is comprehensive, prohibiting all activities related to Levamisole-containing human medicines, including manufacturing, importation, distribution, wholesale supply, retail sale, and direct human use. This broad prohibition underscores the TMDA's determination to completely remove these products from the Tanzanian market. Furthermore, the TMDA has extended a similar ban to veterinary medicinal products containing Levamisole, citing concerns over serious adverse events in animals and the risk of drug residues entering the food chain due to poor withdrawal period management.

This regulatory action by the TMDA is not isolated. Other regulatory bodies globally have taken similar stances. For instance, the European Medicines Agency (EMA) has recommended the withdrawal of all medicines containing Levamisole from the European Union market, citing the same concerns regarding leukoencephalopathy and other severe adverse effects, and concluding that the benefits no longer outweigh the risks. Nigeria is also noted among countries that have banned Levamisole. This international consensus reinforces the scientific basis and public health imperative behind the TMDA's decision, demonstrating a harmonized approach to drug safety surveillance and regulation.

The TMDA's ban on Levamisole-containing medicinal products represents a decisive regulatory intervention aimed at protecting public health from identified serious risks. This action highlights the critical role of pharmacovigilance and the TMDA's statutory powers under the Tanzania Medicines and Medical Devices Act, Cap 219, in ensuring the safety and efficacy of medicines available in the country. The comprehensive nature of the ban, covering all stages of the supply chain and extending to veterinary products, underscores the Authority's commitment to a holistic approach to drug safety.

For legal practitioners, particularly those advising pharmaceutical manufacturers, importers, distributors, and healthcare providers, immediate attention to compliance is paramount. Clients must be advised to halt all activities related to Levamisole-containing products, initiate mandatory recalls within the stipulated 14-day period, and ensure the proper surrender of existing stock. Failure to comply with these directives may result in enforcement actions under applicable medicines and medical devices legislation. Attorneys should also guide clients in reviewing their product portfolios and supply chain agreements to identify and mitigate risks associated with similar active pharmaceutical ingredients that may be subject to future regulatory scrutiny, reinforcing the need for continuous monitoring of global pharmacovigilance trends and domestic regulatory updates.